Patients with Coronary Heart Disease after PCI
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years; 2. It meets the diagnostic criteria of coronary heart disease; 3. Stents were implanted into the target vessels for the first time; 4. It conforms to the definition of successful PCI operation; 5. The patients voluntarily participated in this study, signed a written informed consent form, and were willing to cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Coronary heart disease should exclude myocardial ischemia, injury and necrosis caused by non-coronary atherosclerosis; 2. Those who died within 7 days after PCI; 3. With severe hepatorenal insufficiency, ALT and AST were defined as >5 ULN, and the creatinine clearance rate was less than 30mL/min; 4. Suffer from severe immunodeficiency diseases (such as HIV, etc.), malignant tumors, autoimmune diseases, severe cerebrovascular diseases, blood system diseases, etc., or other diseases that may significantly reduce life expectancy; 5. Pregnant or lactating women, mentally ill; 6. Those who did not take western medicine regularly after operation; 7. Those who participated in any drug clinical trial within 1 month before operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of major adverse cardiovascular events (MACCE) included cardiac death, recurrence of non-fatal myocardial infarction, stroke, revascularization of target vessels and hospitalization due to unstable angina pectoris; | — |
Secondary
| Measure | Time frame |
|---|---|
| complex endpoints(Incidence of cardiac death, non-fatal myocardial infarction and stroke);All-cause mortality;Incidence of cardiac death;Incidence of myocardial infarction;Incidence of ischemic stroke;Incidence of revascularization of target vessels;Incidence of in-stent thrombosis;Admission rate due to heart failure;Changes of cardiac function classification in Killip or NYHA;Changes in laboratory indicators, including blood analysis, biochemistry, blood lipids, blood coagulation, BNP, hsCRP, glycosylated hemoglobin, etc.;Evaluation of comprehensive curative effect, evaluation of angina pectoris symptoms, evaluation of electrocardiogram and changes of TCM syndrome score;The incidence of the total number of compound end-point events;Echocardiography includes changes of left ventricular ejection fraction, left atrial diameter, left ventricular end-diastolic diameter, wall motion and ventricular systolic and diastolic function.; | — |
Countries
China
Contacts
Public ContactWei Wu
The First Clinical College of Guangzhou University of Traditional Chinese Medicine
Outcome results
None listed